Performing lifestyle changes and reducing stroke risk: a process evaluation of a stroke prevention intervention.

BMJ OpenSep 30, 2026 (epub)
Clinical ResearchNeurologyPreventive Medicine / Public Health

Cecilia Johnsson, Eric Asaba, Susanne Guidetti et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated a stroke prevention intervention in Swedish primary healthcare, focusing on implementation processes and mechanisms of change among 122 high-risk participants. The study found that while overall adherence to the intervention was good, specific session attendance varied, with a mean of 3.6 out of 6 sessions attended.

Key findings

  • Mean attendance was 3.6 (SD 2.2) out of 6 sessions.
  • Realistic, activity-focused goal setting was identified as a key mechanism of change.
  • Engagement in everyday activities facilitated sustainable lifestyle changes.
  • Healthcare professionals' delivery was crucial for the intervention's success.

Why it matters

Understanding the implementation and contextual factors influencing stroke prevention interventions can help clinicians optimize their delivery, ultimately improving patient outcomes in high-risk populations.

Source

PubMed · PMID 42816085

Published in BMJ Open. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.